Gabather
0.678
SEK
+35.6 %
GABA
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
1 following
+35.6%
+4.63%
-7.12%
-54.58%
-50.07%
-69.39%
-82.87%
-83.36%
-95.74%
www.gabather.com
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GABA
Daily low / high price
0.678 / 0.698
SEK
Market cap
16.08M SEK
Turnover
413.11 SEK
Volume
603
Financial calendar
Interim report
28.11.2024
Annual report
27.02.2025
Major OwnersSource: Millistream Market Data AB
| Owner | Capital | Votes |
|---|---|---|
| Avanza Pension | 12.6 % | 12.6 % |
| Nordnet Pension | 2.2 % | 2.2 % |
| Investment Aktiebolaget Balticum | 2.1 % | 2.1 % |
| Thomas Nilsson | 1.6 % | 1.6 % |
| Jorgen Jutholm | 1.5 % | 1.5 % |
| Handelsbanken Liv Försäkringsaktiebolag | 1.3 % | 1.3 % |
| Magnus Esselmark | 1.3 % | 1.3 % |
| Kristian Falk | 1.2 % | 1.2 % |
| Anders Asplund | 1.1 % | 1.1 % |
| Anica Kabbenas | 1.1 % | 1.1 % |
ShowingAll content types
Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools